A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
Recruiting
Phase 2
Interventional Study
Rheumatoid Arthritis
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 320 (estimated)
- Sponsor
- AstraZeneca · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
* Inclusion
* Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening.
* Moderately-to-severely active RA as defined by: a. \>= 6 swollen joints on 66SJC and \>= 6 tender joints on 68TJC; b. CRP \> upper limit of normal.
…
Contacts
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
CONTACT